- Capital Cube•58 minutes ago
Categories: Yahoo Finance Get free summary analysis Repros Therapeutics, Inc. reports financial results for the quarter ended June 30, 2016. Analysis Summary numbers: Revenues of USD 0 million, Net Earnings of USD -4.28 million. The company did not record any revenues for the last twelve months making the comparison of net margin versus asset turnover meaningless. RPRX-US‘s earnings ... Read more (Read more...)
Repros Therapeutics to participate as a Sponsor-- developing a therapy specifically designed to treat secondary hypogonadism. THE WOODLANDS, Texas, Sept. 26, 2016-- Repros Therapeutics Inc. ® today noted ...
- Zacks•14 days ago
Repros Therapeutics Inc. (RPRX) announced that the company's UK subsidiary, Renable Pharma Limited, has submitted a marketing authorization application to the European Medicines Agency for one of its pipeline candidate, enclomiphene.
Repros Therapeutics Inc. (RPRX)
NasdaqCM - NasdaqCM Delayed Price. Currency in USD
|Bid||2.07 x 1300|
|Ask||2.08 x 1900|
|Day's Range||2.06 - 2.12|
|52wk Range||0.80 - 8.12|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-2.27|
|Avg Vol (3m)||348,365|
|Dividend & Yield||N/A (N/A)|